Clinical trials: Teriflunomide
Multiple Sclerosis
Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis
Cognitive impairment is common in MS and has devastating impact on functional activities. There is a great demand for medications that will enhance cognitive capacity in MS patients.
- Trial name
- NCT02651545
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Teriflunomide Elimination, Healthy Volunteers
Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride
Primary Objective To determine if colestipol hydrochloride tablets can accelerate the elimination of teriflunomide. Teriflunomide will be administered for 14 days followed by colestipol dosing of 11 days.
- Trial name
- TERCOL (NCT02263547)
- Testing
- teriflunomide, Colestipol
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Derrick Scott Robertson